Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-03-12 23:54 |
PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2019)
|
English | 363.1 KB | ||
| 2020-03-12 23:54 |
PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2019)
|
English | 37.6 KB | ||
| 2020-03-12 13:18 |
Compugen Announces Pricing of $75 Million Public Offering of Ordinary Shares
|
English | 68.0 KB | ||
| 2020-03-12 13:18 |
Compugen Announces Pricing of $75 Million Public Offering of Ordinary Shares
|
English | 37.7 KB | ||
| 2020-03-11 23:26 |
Compugen Announces Commencement of Public Offering of Ordinary Shares
|
English | 134.7 KB | ||
| 2020-03-11 23:26 |
Compugen Announces Commencement of Public Offering of Ordinary Shares
|
English | 37.7 KB | ||
| 2020-03-11 23:18 |
PRELIMINARY PROSPECTUS SUPPLEMENT
|
English | 360.6 KB | ||
| 2020-03-11 23:18 |
PRELIMINARY PROSPECTUS SUPPLEMENT
|
English | 37.7 KB | ||
| 2020-03-09 14:29 |
Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
|
English | 76.5 KB | ||
| 2020-03-09 14:29 |
Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
|
English | 37.7 KB | ||
| 2020-02-28 00:44 |
Form 20-F/A for 2019
|
English | 260.5 KB | ||
| 2020-02-28 00:44 |
Form 20-F/A for 2019
|
English | 37.9 KB | ||
| 2020-02-24 14:49 |
Form 20-F for 2019
|
English | 733.5 KB | ||
| 2020-02-24 14:49 |
Form 20-F for 2019
|
English | 37.9 KB | ||
| 2020-02-20 15:02 |
Compugen Reports Fourth Quarter and Full Year 2019 Results
|
English | 159.2 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
